Genprex, Inc.
GNPX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001595248
No open-market purchases or sales by Genprex, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $154.9K in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in Genprex, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- +7 vs. Q2 2024
- Shares held
- 218.5K
- −40.9K (−15.8%) vs. Q2 2024
- Total value
- $79.7K
- −$409.1K (−83.7%) vs. Q2 2024
- New holders
- 9
- 4 more added
- Sold out
- 2
- 2 more reduced
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting GNPX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 27 | $154.9K |
| Q1 2026 | 27 | $169.0K |
| Q4 2025 | 22 | $13.0K |
| Q3 2025 | 21 | $229.5K |
| Q2 2025 | 28 | $152.9K |
| Q1 2025 | 24 | $93.5K |
| Q4 2024 | 22 | $247.0K |
| Q3 2024 | 21 | $79.7K |
| Q2 2024 | 15 | $510.3K |
| Q1 2024 | 17 | $426.0K |
| Q4 2023 | 36 | $1.16M |
| Q3 2023 | 39 | $2.61M |
| Q2 2023 | 38 | $3.64M |
| Q1 2023 | 39 | $5.42M |
| Q4 2022 | 45 | $5.84M |
| Q3 2022 | 43 | $6.29M |
| Q2 2022 | 42 | $6.11M |
| Q1 2022 | 50 | $10.8M |
| Q4 2021 | 47 | $9.78M |
| Q3 2021 | 49 | $15.8M |
| Q2 2021 | 59 | $19.5M |
| Q1 2021 | 72 | $35.4M |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Genprex, Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| UBS Group AG | 56,359 | $20.4K | 0.00% | +56,268+61,833.0% | Added |
| Virtu Financial LLC | 49,024 | $18.0K | 0.00% | +49,024 | New |
| Two Sigma Securities, LLC | 23,040 | $8.33K | 0.00% | +23,040 | New |
| HighTower Advisors, LLC | 21,027 | $8.00K | 0.00% | +21,027 | New |
| Geode Capital Management, LLC | 16,247 | $5.88K | 0.00% | −250−1.5% | Reduced |
| Vanguard Group Inc | 15,315 | $5.54K | 0.00% | 00.0% | Unchanged |
| HRT Financial LP | 15,540 | $5.00K | 0.00% | +15,540 | New |
| BlackRock, Inc. | 9,485 | $3.43K | 0.00% | +9,485 | New |
| Tower Research Capital LLC (TRC) | 9,271 | $3.35K | 0.00% | +5,375+138.0% | Added |
| Nemes Rush Group LLC | 250 | $745 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 1,574 | $569 | 0.00% | +87+5.9% | Added |
| Bank of America Corp | 433 | $156 | 0.00% | +4+0.9% | Added |
| Aspire Private Capital, LLC | 400 | $145 | 0.00% | +400 | New |
| Ashton Thomas Securities, LLC | 127 | $46 | 0.00% | +127 | New |
| Allworth Financial LP | 125 | $46 | 0.00% | +125 | New |
| Group One Trading, L.P. | 114 | $41 | 0.00% | −714−86.2% | Reduced |
| Advisor Group Holdings, Inc. | 58 | $20 | 0.00% | +58 | New |
| VitalStone Financial, LLC | 10 | $4 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 5 | $2 | 0.00% | 00.0% | Unchanged |
| Global Retirement Partners, LLC | 5 | $2 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 63 | $0 | 0.00% | 00.0% | Unchanged |
| Armistice Capital, LLC | 0 | $0 | 0.00% | −218,000−100.0% | Sold out |
| Brown Brothers Harriman & Co | 0 | $0 | 0.00% | −2,500−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |